Elevance Health, Inc. $ELV Shares Sold by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. decreased its holdings in Elevance Health, Inc. (NYSE:ELV) by 6.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,603 shares of the company’s stock after selling 3,580 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Elevance Health were worth $19,287,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. BlackRock Inc. purchased a new position in shares of Elevance Health during the 2nd quarter worth about $7,344,424,000. State Street Corp grew its holdings in Elevance Health by 1.3% in the second quarter. State Street Corp now owns 10,426,610 shares of the company’s stock valued at $4,032,283,000 after purchasing an additional 137,914 shares during the period. Wellington Management Group LLP grew its holdings in Elevance Health by 12.0% in the second quarter. Wellington Management Group LLP now owns 9,213,513 shares of the company’s stock valued at $3,563,142,000 after purchasing an additional 984,976 shares during the period. First Eagle Investment Management LLC increased its position in Elevance Health by 1.4% during the second quarter. First Eagle Investment Management LLC now owns 4,188,196 shares of the company’s stock worth $1,619,701,000 after purchasing an additional 55,905 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in Elevance Health during the second quarter worth approximately $1,246,349,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Stock Performance

NYSE ELV opened at $435.26 on Thursday. The firm has a market capitalization of $94.39 billion, a P/E ratio of 19.34, a P/E/G ratio of 2.29 and a beta of 0.70. Elevance Health, Inc. has a 1-year low of $274.84 and a 1-year high of $450.69. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.52 and a quick ratio of 1.52. The business’s 50-day simple moving average is $406.59 and its 200-day simple moving average is $389.52.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.71 by $2.28. The business had revenue of $50.44 billion during the quarter, compared to analysts’ expectations of $49.28 billion. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%. The company’s revenue for the quarter was up .7% on a year-over-year basis. During the same quarter in the previous year, the business earned $6.03 EPS. Equities analysts predict that Elevance Health, Inc. will post 27.20 EPS for the current year.

Elevance Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 18th. Shareholders of record on Friday, December 4th will be given a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a yield of 1.6%. The ex-dividend date of this dividend is Friday, December 4th. Elevance Health’s payout ratio is 30.58%.

Key Headlines Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Quarterly results exceeded expectations: Adjusted earnings were $6.99 per share versus the roughly $4.66–$4.71 consensus estimate, while revenue reached $50.44 billion, above expectations of about $49.22 billion. Earnings also increased from $6.03 per share a year earlier. Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance
• Positive Sentiment: 2026 outlook was raised: Management lifted its underlying earnings baseline to at least $26.75 per share, citing disciplined expense management and better medical-cost performance. Elevance also expects at least 12% adjusted EPS growth in 2027 from the higher earnings base. Elevance lifts 2026 profit forecast on better medical cost management
• Positive Sentiment: Carelon remained a growth driver: Strength in the services business helped offset pressure elsewhere, supporting management’s confidence in future growth. Elevance named Jeff Park president of Carelon, effective December 1, to lead its next expansion phase. Elevance Health Names Jeff Park President of Carelon
• Neutral Sentiment: Elevance declared a quarterly dividend of $1.72 per share, or $6.88 annualized, representing a yield of approximately 1.6%. The payout supports shareholder returns but is unlikely to be the primary near-term trading catalyst.
• Negative Sentiment: Membership pressure remains a concern: The earnings beat occurred despite declining medical membership, increasing investor focus on enrollment trends and the company’s ability to sustain growth.
• Negative Sentiment: Although cost management improved, Elevance operates on a thin net margin, and continued medical-cost inflation or weaker enrollment could limit the benefit of the raised forecast. The shares have also recently traded near a 52-week high, potentially increasing profit-taking risk.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Sanford C. Bernstein set a $488.00 price target on shares of Elevance Health in a research note on Thursday, July 16th. The Goldman Sachs Group reissued a “neutral” rating and set a $395.00 price objective on shares of Elevance Health in a research note on Thursday, July 16th. TD Cowen boosted their price objective on shares of Elevance Health from $400.00 to $465.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Royal Bank Of Canada dropped their price objective on Elevance Health from $439.00 to $424.00 and set a “sector perform” rating for the company in a report on Thursday, July 16th. Finally, Barclays increased their target price on Elevance Health from $457.00 to $469.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Fifteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $441.71.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.